Polaryx Therapeutics, Inc.
PLYX · Pharmaceutical Preparations · 47.3M shares · EDGAR filings ↗
Reference price $4.07 · est. market cap ~$193M — last insider purchase, 2026-05-27 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
D42Clinical/early-stage biotech — rare-disease clinical, well-funded.
Strengths
- Liquidity — current ratio 8.6 (75th)
Risks
- Pre-revenue, deep losses — per metrics
- Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
- Binary clinical & funding risk — per 10-K
Notable findings
- Material weakness● We previously identified a material weakness in our information technology general controls that has since been remediated
- Insider buyingInsider buying — 2 open-market buy(s) by 2 insider(s) (cluster of 2 insiders, ~$367,994, last 6mo) Form 4 ↗
- Notable holderHeld by 2 notable fund(s): STATE STREET CORP, GOLDMAN SACHS GROUP INC (as of 2026-03-31)
- Trial readout soonUpcoming trial readout ~2026-12-31 — PHASE3 · Juvenile Neuronal Ceroid Lipofuscinosis
- Trial resultTrial topline data reported — see 8-K for outcome 8-K ↗
Key metrics
Return on equity
-196.8%
Return on assets
-173.8%
Current ratio
8.5×
Tangible book value
$5M
Cash & investments
$5M
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-05-27 | Yang Alex Keun Mo | Buy | 88K | $4.07 |
| 2026-02-18 | Landis G. Michael | Buy | 2.9K | $2.79 |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT04637282 ↗ | Safety, Tolerability, and Efficacy of PLX-200 in Patients With CLN3 Juvenile Neuronal Ceroid Lipofuscinosis | PHASE3 | Not Yet Recruiting | 2026-12-31 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Notable events (8-K)
| Date | Items | |
|---|---|---|
| 2026-05-28 | Material agreement3.02Reg FDExhibits | filing ↗ |
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-05-28 | 2026-05-27 | 0001213900-26-062155 ↗ |
| 10-Q | 2026-05-15 | 2026-03-31 | 0001213900-26-056973 ↗ |
| 10-K | 2026-03-24 | 2025-12-31 | 0001213900-26-033064 ↗ |